Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-02-26 | Reverse | 1:15 |
Karyopharm Therapeutics develops and commercializes SINE compounds targeting nuclear export, with lead drug XPOVIO for multiple myeloma and lymphoma, licensed in Europe and Latin America, focusing on cancer treatments.
XPOVIO® is an oral cancer treatment approved for multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma, serving as Karyopharm's flagship product focused on targeting cancer's fundamental mechanisms.
Karyopharm Therapeutics announced comprehensive financing and capital structure transactions providing the company with $100 million in financial flexibility and additional capital. This strategic move extends the company's cash runway into the second quarter of 2026, a critical development as it de-risks the company's financial position ahead of the highly anticipated top-line data from its pivotal Phase 3 SENTRY trial in myelofibrosis.
In a significant strategic move to preserve capital, Karyopharm Therapeutics announced a restructuring that includes a 20% reduction of its workforce. This decision is part of a broader, board-led review of strategic and financing options, which could include a merger, sale of the company, or other transactions, as it faces a cash crunch and upcoming debt maturities.
NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee.
Karyopharm Therapeutics (NASDAQ: KPTI - Get Free Report) and Alpha Cognition (NASDAQ: ACOG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations. Analyst Ratings This is a breakdown of
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
 XFOR | $2.90 | COMPARE |
 TELO | $1.25 | COMPARE |
 INMB | $1.94 | COMPARE |
 ALGS | $5.57 | COMPARE |
 MDCX | $0.17 | COMPARE |
 SNTI | $0.34 | COMPARE |
